UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): January 22,
2021
EXACTUS, INC.
(Exact
name of the registrant as specified in its charter)
Nevada
|
000-55828
|
27-1085858
|
(State
or other jurisdiction of
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
80 NE 4th Avenue, Suite 28, Delray Beach, FL 33483
(Address
of principle executive offices) (Zip code)
Registrant’s
telephone number, including area code: (561) 455-4822
_____________________________________________________________________
(Former
name or address if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions (see General Instruction A.2
below):
[
] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425).
[
] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12).
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)).
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)).
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol(s)
|
|
Name of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
SECTION
1 – REGISTRANT’S BUSINESS AND OPERATIONS
Item
1.01
Entry
Into a Material Definitive Agreement
Ceed2Med, LLC
On
January 22, 2021, we entered into a Settlement and Release
Agreement (the “Agreement”) with Ceed2Med, LLC
(“C2M”), a former affiliate of the company. Over the
course of 2018-2019 we had entered into a series of agreements for
product and funding with C2M in connection with our seed-to-sale
strategy for our hemp-derived CBD business, to secure farming
rights and expertise, and to secure product, distribution and
funding. We previously issued 10,000 shares of our Series E
Preferred Stock convertible into 6,250,000 shares of common stock
to C2M. Pursuant to the Agreement, C2M will permit us to transfer
all outstanding shares of Series E Preferred stock to settle
various third-party claims and obligations, avoiding dilution in
furtherance of our ongoing restructuring efforts. Under the
Agreement, all existing agreements, obligations and claims have
been cancelled and rescinded, we exchanged full mutual releases and
we will receive a cash payment of $200,000 on or before February 5,
2021.
The
foregoing description is a summary of the material terms of the
Agreement, which is filed herewith as Exhibit 10.1. The Agreement
contains additional terms, covenants, and conditions and should be
reviewed in its entirety for additional information
Dr. Krassen Dimitrov, Digital Diagnostics, Inc., and KD Innovation
Ltd.
On
January 22, 2021, we settled all outstanding claims and obligations
to Dr. Krassen Dimitrov, a former director, Digital Diagnostics,
Inc., and KD Innovation Ltd. as previously described under Item 13.
Certain Relationships and Related Transactions, and Director
Independence in our Annual Report on Form 10K for the fiscal year
ended December 31, 2020. Previously, we had recorded an obligation
on our balance sheet of $575,000 for claims asserted against us.
The terms of the settlement are confidential, other than no cash
was paid in connection with the settlement. As a result, we expect
to eliminate $575,000 of indebtedness from our financial statements
during the quarter ended March 31, 2021.
SECTION 3 – SECURITIES AND TRADING MARKETS
Item
3.02
Unregistered
Sales of Equity Securities
On
January 22, 2021, our board of directors authorized the issuance of
up to approximately 25,000,000 shares common stock in settlement of
approximately $1,250,000 in outstanding liabilities and accounts
payable owed to 11 persons. Such amount and number of shares is
inclusive of a payment to C2M and under the Krassen Settlement
described in Item 1.01 above.
On
January 22, 2021, our board of directors approved private offers to
be made through January 31, 2021, subject to extension, to holders
of our Series A, Series B-1 and Series B-2 preferred stock with
inducements to voluntarily convert preferred shares into our common
stock with full general releases of all claims against the company.
Holders of Series A Preferred Stock may exchange their shares at a
conversion price of $0.025 per share. Holders of our Series B-1 and
Series B-2 Preferred Stock may exchange their shares at a
conversion price equal to .25 shares of common stock for each share
of preferred stock exchanged. There
were 323,019 shares of Series A, 1,650,000 shares of Series B-1 and
7,516,000 shares of Series B-2 preferred stock outstanding as of
September 30, 2020. Outstanding shares of Series B-1 and Series B-2
convertible stock were convertible into 206,250 shares of common
stock and 939,500 shares of common stock, respectively, as of
December 31, 2019 at the original conversion rate of .125 shares of
common stock for each share of preferred stock.
We
agreed to permit transfer of Series E Preferred Stock and
conversion into 6,250,000 shares of common stock ($1.60 per share)
and issue 8,000,000 shares of our restricted common stock in
connection with the settlement with C2M as described in Item 1.01
above.
The foregoing issuances do not involve any public offering
and are exempt from registration pursuant to Section 4(a)(2) of the
Securities Act of 1933, as amended.
SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item
5.02
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of CertainOfficers; Compensatory Arrangements of
Certain Officers
Appointment of Larry Wert as Executive Chairman
On
January 22, 2021, Larry Wert was appointed to the position of
Executive Chairman of our Board of Directors. Mr. Wert has
served as a member of our Board of
Directors since April 29, 2020. Mr. Wert has over 40 years in broadcasting. He served as
the President of Broadcast Media for Tribune Media Company from
2013 ( post bankruptcy ) through September of 2019 ( $4.8 billion
sale to NEXSTAR Media.)
He was responsible for
overseeing the strategy and day-to-day activities of Tribune Media
Company’s forty-two owned or operated television stations,
their related websites, digital properties and helped
navigate TRCO M&A. Wert
previously served on the NAB TV Board of Directors, Fox Board and
the CBS Board of Governors. Prior to his time at Tribune Media, Mr. Wert
served from 1998 until 2013 as the President and General Manager of
WMAQ-TV, and other leadership roles at NBC Universal.
Mr. Wert started his career at
Leo Burnett Advertising in Chicago in 1978, and moved on to
television sales with ABC TV. In 1989, Mr. Wert shifted to radio as
president and general manager of WLUP-97.9 FM and AM 1000 in
Chicago, better known as “The Loop.” In 1996, he was
named president of Evergreen Media. When it merged with Chancellor
Broadcasting he became senior vice president of Chancellor,
which was sold to Clear Channel in 1999 for $4.4 billion.
Wert now serves on a variety of boards, and advisory roles in
liquor, home healthcare, gaming, original content and other
technology.
Strategic Alternatives Committee
On
January 22, 2021, our Board of Directors formed a Strategic
Alternatives Committee, for the purpose of evaluating potential
acquisitions, mergers, and other strategic business combinations
for the company. The new committee consists of Directors Larry Wert
and Julian Pittam, with Mr. Wert serving as its
chairman.
Issuance of Stock Options to Key Executives and
Directors
On
January 22, 2021, our Board of Directors approved the issuance of
two-year options to purchase common stock. All such options may be
exercised on a cash or cashless basis at any time prior to the
company entering into an acquisition with a minimum value of
$5,000,000 and shall be automatically exercised on a cashless
“net exercise” basis immediately prior to closing of
such acquisition. In addition, options issued to Mr. Alberttis are
subject to further vesting conditions which require he continue to
be employed at the time of any acquisition in excess of $5,000,000
(50%) provided he agrees to a separation agreement in which he
voluntarily resigns from all positions with the company and
executes a release with confidentiality and non-disparagement
provisions, and additionally if no acquisition is closed on or
prior to the due date for the company’s annual report on Form
10K for the fiscal year ended December 31, 2021 he shall have
timely filed and executed all certifications required for such
filing (50%). Options issued to Mr. Johnson vest 50% on the date of
issuance and 50% upon closing of an acquisition with a value of
$5,000,000 provided he agrees to a separation agreement in which he
voluntarily resigns from all positions with the company and
executes a release with confidentiality and non-disparagement
provisions.
Larry
Wert
|
Director,
Executive Chairman, Strategic Advisory Committee Chair
|
Options
to purchase 3,500,000 shares of common stock at $0.025 per
share
|
Julian
Pittam
|
Director,
Strategic Advisory Committee
|
Options
to purchase 1,500,000 shares of common stock at $0.025 per
share
|
Daniel
Alberttis
|
COO
|
Options
to purchase 2,500,000 shares of common stock at $0.025 per share,
subject to vesting
|
Andrew
Johnson
|
Chief
Strategy Officer
|
Options
to purchase 3,500,000 shares of common stock at $0.025 per
share
|
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
As more
fully described in Item 1.01 and Item 3.02 above, upon conversion
of our Series A, Series B-1, Series B-2 and 18 shares of our Series
D Preferred Stock expected to be converted we expect to file a
Certificate of Cancellation with the Secretary of State of the
State of Nevada eliminating such series from our authorized series
of preferred stock.
On
January 22, 2021, our Board of Directors authorized a possible
reverse split of our common stock at a ratio of between 1 share for
every 40 shares held and 1 share for every 50 shares held, to be
determined in the further discretion of the Board. The reverse
split is subject to approval by our shareholders unless the number
of authorized shares of our capital stock is reduced
proportionately in accordance with Nevada law, and may be
authorized, if at all, in connection with a recapitalization
required in connection with an acquisition or similar event. The
timing of shareholder approval, whether the reverse split will
ultimately be approved by our shareholders, and the ratio is
currently unknown.
Item 7.01
Regulation FD Disclosure.
On
January 25, 2021, we released the
press release furnished herewith as Exhibit 99.1. The Company also
reiterated that it is exploring strategic alternatives which could
include one or more mergers or acquisitions in related or unrelated
businesses, asset disposals, and refinancings.
Section 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item
9.01
Financial
Statements and Exhibits
Exhibit No.
|
Description
|
10.1
|
Settlement
and Release Agreement with Ceed2Med, LLC(1)
|
|
Agreement
(redacted) with Dr. Krassen Dimitrov, Digital Diagnostics, Inc. and
KD Innovation, Ltd. (2)
|
|
Press
Release dated January 25, 2021
|
(1)
This Exhibit will
be filed as an Exhibit to our Annual Report on Form 10-K for the
fiscal year ended December 31, 2020.
(2)
Portions of this
Exhibit have been redacted
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on behalf of the
undersigned hereunto duly authorized.
|
EXACTUS,
INC.
|
Date:
January 27, 2021
|
By:
/s/ Alvaro Daniel
Alberttis
Alvaro
Daniel Alberttis
Principal
Executive Officer
|
Exhibit 10.2
SETTLEMENT
AGREEMENT
[Note – Certain identified information has been excluded from
this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. The redacted
information is indicated with brackets.]
Common Stock means the common stock, par value $0.0001 per
share, of Exactus, Inc.
Consulting Agreement means that certain Consulting Agreement
dated as of by and between EDI and KDI.
DDI means Digital Diagnostics, Inc., an Australian
corporation.
Default shall have the meaning ascribed to such term in
Section E hereof.
Effective Date means the date of execution of this Agreement
by the Company, EBI, KD, KDI, and DDI.
Exactus or the Company means Exactus, Inc. a Nevada
corporation including its subsidiaries, predecessors, successors
and assigns (for the absence of doubt, including Exactus
Biosolutions, Inc. and Exactus Diagnostics, Inc.).
KD means Dr. Krassen Dimitrov.
KDI means KD Innovation, Ltd. a limited liability company
organized under the laws of Taiwan,
License Agreement means that
certain Collaboration and License Agreement dated as of January 19,
2016 by and between DDI and EBI, as amended or supplemented from
time to time.
Option Agreement shall have the
meaning ascribed to such term in Section F
hereof.
Permitted Transfers shall have
the meaning ascribed to such term set forth on Exhibit B annexed hereto.
Retained Shares means [
].
Released Company Parties are Exactus, its past or present
officers, directors, and employees, consultants, subsidiaries,
insurers, co-insurers or reinsurers, attorneys, advisors, trustees,
executors, heirs, spouses, marital communities, executors, estates,
affiliates, subsidiaries and successors-in-interest.
Released KD Parties are KD, KDI, DDI, its past or present
officers, directors, and employees, consultants, subsidiaries,
insurers, co-insurers, or reinsurers, attorneys, advisors,
trustees, executors, heirs, spouses, marital communities,
executors, estates, affiliates, subsidiaries, and
successors-in-interest.
Settling Parties are Company, KD, KDI and DDI.
Settlement Shares shall have
the meaning ascribed to such term in Section C.1
hereof.
B.
The
Agreement Is Binding
Upon
execution of this Binding Agreement by the Settling Parties, the
provisions of this agreement shall be a binding and enforceable
contract, settlement and release enforceable against the
Settling Parties.
The Settling
Parties will prepare all
additional necessary or appropriate settlement documents to
effectuate the intent and purposes of this Agreement. Exactus is
hereby authorized and empowered to take all action necessary or
appropriate to effectuate the Settlement Terms set forth herein,
including, without limitation, a power of attorney and to execute a
stock power to provide instructions to the transfer agent for
Common Stock to transfer the Settlement Shares (as defined below)
as provided herein and to effectuate the Option Agreement (as
defined below).
1.
Company shall issue
and KD shall receive [ ] on
the Effective Date (the "Settlement Shares") and KD shall enter
into an Option Agreement substantially in the form of Exhibit A annexed hereto. Within three
business days of the Effective Date, Company shall transmit to KD a
letter from the Company's Transfer Agent documenting the issuance
of the Settlement Shares. Provided the option rights granted in the
Option Agreement have not been exercised, upon the request of KD,
Company shall assist KD to effectuate deposit of the Settlement
Shares to a single brokerage of KD's choice. Company shall provide
authorization to the Company's transfer agent and at Company's cost
a legal opinion required for such deposit, provided KD shall
provide such authorizations and instructions required of KD by the
transfer agent (Including a currently dated medallion guaranteed
stock power, representation letter in customary form and transfer
agent instructions, and board resolutions of KD necessary to issue
a Rule 144 opinion and transfer shares), and each will provide any
other formalities necessary for deposit into street name in the
brokerage account as reasonably requested by the transfer
agent.
2.
KD, KDI and DDI
agree to the covenants set forth in Exhibit B.
3.
The License
Agreement, Consulting Agreement and any and all other contracts,
agreements, understandings or arrangements by and between the
parties concerning the subject matter hereof are terminated and of
no further force or effect.
4.
Any and all
letters, instructions, authorizations, claims, or assertions,
purported on behalf of KD, KDI or DDI are hereby withdrawn and of
no force or effect. KD, KDI and DDI acknowledge and agree that no
amounts are due and owing to any of them, and approves cancellation
and removal from the financial statements of the Company all
amounts, contingent or otherwise, that may become due or owing to
any of KD, KDI of DDI, including, without limitation, any
Consulting Fees, License Fees, interest, penalties, legal fees,
expense reimbursements, options, warrants or rights, which are
hereupon cancelled, discharged and waived In all
respects.
5.
[ ] shall be “restricted
securities” as defined in paragraph (a) of Rule 144 under the
Securities Act of 1933, as amended (the "Act") acquired for
investment purposes only and without the intent to make a further
distribution of such shares, issued pursuant to an exemption from
the registration requirements of the Securities Act, under Section
4(a)(2) of the Act and the rules and regulations promulgated
thereunder. Certificates representing the shares of the Company
shall bear a restrictive legend in substantially the following
form:
The
shares represented by this certificate have not been registered
under the Securities Act of 1933, as amended, and may not be
offered for sale, sold, or otherwise disposed of, except in
compliance with the registration provisions of such Act or pursuant
to an exemption from such registration provisions, the availability
of which is to be established to the satisfaction of the Company,
and are subject to the By-laws of the Company which contain certain
restrictions on transfer and are available upon request to the
Secretary of the Company.
The
shares represented by this certificate are subject to an Option
Agreement a copy of which will be provided upon
request.
6.
The
Settling Parties shall not be liable for any other amounts or
obligations other than upon the occurrence of Default
hereunder.
Released KDI Parties release and discharge the Released Company Parties from any claim,
demand, action, or cause of action, known or unknown, which arose
at any time from the beginning of time to the date of this binding
agreement, and waive all claims against or in any way connected
with the Released Company
Parties or their officers or directors, including, without
limitation, any claim, demand, action, cause of action, including
money damages and claims for attorneys’ fees, all subject to
this Agreement.
Released Company Parties release and discharge the
Released KDI Parties from
any claim, demand, action, or cause of action, known or unknown,
which arose at any time from the beginning of time to the date of
this binding agreement, and waive all claims against or in any way
connected with the Released KDI
Parties or their
officers and directors, including, without limitation, any claim,
demand, action, cause of action, including money damages and claims
for attorneys’ fees.
The Settling
Parties will prepare all
necessary settlement documents to confirm the settlement and the
dismissal, with prejudice of that certain arbitration commenced
before the American Arbitration Association, Case No
01-19-0002-8473-2-BM (the “Dismissed Arbitration”). The
releases herein shall include all claims raised in the Dismissed
Arbitration or that could have been raised in the Dismissed
Arbitration or brough in any other venue or forum under the License
Agreement or the Consulting agreement.
In the
event that within three business days of the Effective Date the
Company fails to provide proof of issuance of Settlement Shares to
KD or in the event that within fourteen (14) days following the six
(6) month anniversary of the Effective Date, the Company fails to
remove the restrictive legend required under Section C.5 hereof,
provided KD has provided the transfer agent with all required
documents from KD, and remit to the account designated by KD the
Settlement Shares, unless the Option Agreement has been exercised
and the Optionee has tendered to KD immediately available funds for
the option exercise as set forth in the Option Agreement, the
Company will be in default. Pursuant to any default KD may then
email a notice of default to counsel for the Company at
rcarmel@cmfllp.com,
demanding cure of default, which shall be cured if the Option is
immediately exercised and the payment is received by KD within ten
(10) days of the notice email to an account designated in writing
by KD. If payment is not received within ten (10) days of the
demand to cure the default The Company hereby irrevocably
authorizes the Prothonotary or any attorney admitted to practice
before any court of record in the United States or the clerk of
such court to appear on behalf of Company in any court in one or
more proceedings, or before any clerk thereof or prothonotary or
other court official, and to confess judgment against Company in
favor of Krassen Dimitrov in the amount of [ ], together with any other charges,
costs and expenses for which Borrower is liable under this
Agreement, and together with fees of counsel in the reasonable
amount of five percent (5%) of all of the foregoing and costs of
suit, releasing all errors and waiving all rights of
appeal.
KD
shall file an Affidavit in any such proceeding, which shall state
substantially the following:
“KD hereby
certifies and affirms under penalty of perjury that pursuant to
that certain Settlement Agreement dated as of ____ and Option
Agreement dated as of _____ Exactus, Inc. is in default of such
agreements’ requirement to cause to be deposited shares of
Common Stock into a brokerage account and the Option as defined
therein has not been exercised. KD has satisfied each and every
obligation (including, if applicable to provide documentation
requested by the transfer agent in order to issue a Rule 144
opinion) and provide written wiring instructions to Exactus, Inc.
and any Option holder. Accordingly, Exactus Inc., is required to
pay the amount of _____ to KD Notice of Default has been delivered
to Exactus, Inc. and its counsel at least 14 days prior to this
request for an order in accordance with the Settlement Agreement a
true and correct copy of which is affixed
hereto.”
If a
copy of this Agreement, verified by affidavit, shall have been
filed in such proceeding, it shall not be necessary to file the
original as a warrant of attorney. Company hereby waives the right
to any stay of execution and the benefit of all exemption laws now
or hereafter in effect. No single exercise of this warrant and
power to confess judgment shall be deemed to exhaust this power,
whether or not any such exercise shall be held by any court to be
invalid, voidable or void. Interest shall continue to accrue after
entry of judgment hereunder, by confession, default, or otherwise,
at a rate equal to twelve (12%) percent per annum from the
Effective Dated through and including the date of
payment.
The
Company shall issue a press release and KD shall not object to a
press release language that is substantially as follows:
“The parties have reached
agreement as to a resolution of all issues and are pleased to
announce the settlement of their disputes. Dr. Krassen is pleased
that their disputes have been fully resolved and looks forward to
the continued success of Exactus.”
Commencing at the
Effective Date the KDI agrees that other than Permitted Transfers,
none of KDI Released Parties shall sell Common Stock other than as
set forth on Exhibit
B annexed hereto. Any attempted transfer or disposition of
Common Stock in violation or breach of this Agreement shall be null
and void and of no effect.
The
Settling Parties shall enter into an Irrevocable Option Agreement
(the “Option
Agreement”), effective as of the date hereof, in such
form and subject to such terms and conditions as the Settling
Parties shall agree, which shall be a condition to the
effectiveness of this Agreement.
This
binding agreement and settlement shall be treated as jointly
drafted and will not be construed against any Settling Party as the
drafter.
Nothing
in this binding agreement shall be construed as an admission of
liability, or the absence of liability, by any Settling Party.
From
the Effective Date, the Settling
Parties agree to keep the terms of the agreement
confidential other than as required to effectuate the intent and
purposes of this agreement, other than as required to perform the
Settlement Agreement, the Option or the transfer of Settlement
Shares into a brokerage account, in connection with the preparation
of any audit, tax return or financial statements, any and all SEC
reporting, and in connection with any investor or regulatory
inquiry, due diligence investigation, or investment, loan, contract
or credit application or similar business purpose.
From
the Effective Date each Settling Party shall not disparage any of
the other Settling Parties.
KD
agrees that he shall refrain from any future posts on any stock or
company message boards except as set forth announcing resolution of
the Settling Parties dispute, and shall withdraw from the position
of moderator on the Company’s “iHub” message
board.
This
agreement will be interpreted and governed by the internal laws of
the State of Florida without regard to conflicts of law rules. The
exclusive forum for the adjudication of any disputes arising under
this binding agreement or any of the Settling Parties shall be the
United States District Court for the Southern District of Florida
or, in the event that the United States District Court for the
Southern District of Florida lacks subject-matter jurisdiction, the
Circuit Court of the State of Florida sitting in Broward County,
Florida Each Settling Party accepts and consents to personal
jurisdiction and waives any objection to venue in the identified
courts.
This
Settlement Agreement is intended to be a binding agreement that
sets forth all material terms and obligations of the parties
hereto, and the parties hereto shall use their best efforts to
consummate the settlement contemplated herein.
This
Agreement may be executed in any number of counterparts (including
facsimile or PDF), each of which shall be deemed an original but
all of which together shall constitute one and the same
instrument.
Each
party hereto acknowledges that it has been represented by
independent legal counsel in the preparation of the Agreement. Each
party recognizes and acknowledges that counsel to the Company has
represented other shareholders of the Company and may, in the
future, represent others in connection with various legal matters
and each party waives any conflicts of interest and other
allegations that it has not been represented by its own
counsel.
[signature page
follows]
IN WITNESS WHEREOF, this binding
agreement is duly executed as of the dates below.
Exactus, Inc.
By:
Larry
Wert
Title:
Executive Chairman
Date:
|
Dr. Krassen Dimitrov
______________________
Date:
KD Innovation, Ltd.
By:
Title:
Date:
Digital Diagnostics, Inc.
By:
Title:
Date:
|
EXHBIT A
OPTION AGREEMENT
EXHIBIT B
Confidentiality. The Settling
Parties agree that the contents of the discussions between the
parties hereto, are confidential, and, except as required by law or
administrative or judicial process or as may be required for any
party to enforce its rights hereunder, shall not be disclosed by
the Settling Parties to anyone other than its respective officers,
directors, employees or representatives that have a need to know
and are made aware of the confidential nature of such communication
prior to such disclosure. KD, KDI and DDI acknowledge that the
Company has certain public disclosure obligations, including, but
not limited to, under the Securities Act of 1934, as amended, and
that such parties may be required to disclose the existence, terms
and content of this agreement, as well as the transactions
contemplated hereby and thereby, among other
matters.
From and after the Effective Date until the second (2nd)
anniversary of the Effective Date, the Released KD Parties shall
not interfere with any relationship, contractual or otherwise,
between the Company and any supplier, distributor, co-venturer or
joint-venturer of the Company to discontinue or reduce its business
with the Company.
Permitted Transfers. From and
after the Effective Date through and including the six (6) months
anniversary thereof, the Released KD Parties shall not sell Common
Stock other than: (i) to any trust, partnership, corporation or
other entity formed for the direct or indirect benefit of the
undersigned or the immediate family of the undersigned, provided
that prior to such transfer a duly authorized officer,
representative or trustee of such transferee agrees in advance in
writing to be bound by and the Shares are subject to, the
provisions of this Agreement; (ii) to any of the equity owners of
the undersigned or the equity owners of such parties, provided that
prior to such transfer the transferee executes an agreement stating
that the transferee is receiving and holding the Shares subject to
the provisions of this Agreement; (iii) in a private transaction
effected outside of the facilities of the principal trading market
for the Common Stock provided that such transferee agrees in
advance in writing to be bound by and the Common Stock is subject
to, the provisions of this Agreement; (iv) to any bidder(s) in an
offer to purchase a majority of the outstanding equity securities
of the Company made in a tender offer or similar offer made to
holders of Common Stock generally; or (v) pursuant to the Option
Agreement. On after the six (6) months anniversary of the Effective
Date, the Released KD Parties shall not have any restriction on the
offer and sale of Common Stock in open market
transactions.
Exhibit 99.1
Exactus, Inc. Announces 2021 Debt Reduction and Settlement of
Claims
- Settlements of over $1,250,000 in Liabilities - - Preferred Stock
Conversions -
DELRAY BEACH, FL / January 25, 2020 / Exactus, Inc. (OTCQB:
EXDI) (the “Company”) provides a series of announcements
including 1) overall debt reduction of approximately $1,250,000; 2)
settlement of outstanding claims for license and consulting fees;
3) termination of Ceed2Med affiliation & Series E Preferred
Stock cancelation; and 4) conversion of Series A, Series B-1,
Series B-2, and Series D Preferred.
As the company continues its restructuring process, it has
dramatically cut costs, improved operational capabilities, built
its digital sales infrastructure Marketing Automation & Sales
System (“MASS”), entered into a manufacturing
agreement, launched its private label division, and settled the
majority of its liabilities and claims.
Executive Chairman of the Board, Larry Wert commented, “Since
the initiation of the restructuring process, the company has worked
hard to improve our path to grow shareholder value. We have
significantly cleaned up our balance sheet and resolved several
issues and obligations as we continue to operate. The company is
exploring several opportunities both in and outside the CBD sector.
We anticipate that we will have more exciting news in the near
future as we are engaged in various growth
initiatives.”
The Company took these additional steps as part of its previously
announced efforts to reduce operating costs and streamline
operations in order to position the Company for future
acquisitions.
1)
Following an extensive review, the Company’s outstanding
payables and obligations were reduced as follows:
Approximately $1,250,000 in liabilities and payables were
eliminated consisting of approximately $575,000 in liabilities
previously recorded on the balance sheet for payment to a licensor
for Fibrilizer and Matrilizer technology; in addition, liabilities
associated to consultants, unpaid loans, advances, bonuses and
compensation payable to management of the Company were converted
into shares of common stock.
2)
KDI Innoviation Ltd. / Dr. Krassen Dimitrov Arbitration Settlement
and Release:
Dr. Krassen stated “I am pleased that our disputes have been
fully resolved and I look forward to the continued success of
Exactus.”
During September 2019 an arbitration had been commenced against the
Company by its former director Dr. Krassen Dimitrov alleging breach
of a consulting agreement and for license fees claimed to be due
and owing to KDI Innovation, Ltd., his affiliate. The Company
asserted various counterclaims and during 2020 the parties agreed
to voluntarily dismiss the arbitration in order to enter into
direct negotiations for settlement. During January 2021, the
parties reached agreement as to a resolution of all issues and are
pleased to announce the settlement of their disputes. The terms of
the settlement are confidential other than no cash was
paid.
3)
Termination of Ceed2Med, LLC Affiliation / Series E Preferred Stock
Cancellation:
On July 31, 2019 we granted 10,000 shares of our Series E Preferred
Stock to Ceed2Med, LLC in connection with our efforts to enter into
a seed to sale strategy for our hemp-derived CBD business and
secure farming rights and expertise. In addition, between 2018-2019
we entered into a series of agreements for product and funding with
Ceed2Med, LLC. On January 21, 2021 we entered into a Settlement
Agreement with Ceed2Med, LLC and its principals cancelling all
agreements, obligations and claims and providing full mutual
releases of the Company and such persons. In connection with the
settlement, Ceed2Med, LLC agreed to assignment of all rights to
convert its outstanding shares of Series E Preferred Stock at a
price of $1.60 per share to third parties in connection with
settlement and releases of third party claims, resulting in no
further dilution from issuances of settlement shares other than the
right for Ceed2Med to have received such shares upon conversion and
thereupon the Series E Preferred Stock was simultaneously converted
into shares of common stock.
4)
Series A / Series B-1 / Series B-2 / Series D Preferred
Conversions:
The Company has extended a limited period of time for all holder of
Series A, Series B-1, Series B-2, and Series D Preferred stock to
convert their shares into Common Stock in order to secure releases,
eliminate claims, and simplify the cap table. The Company expects
to secure full conversion of all shares and exchange mutual
releases with the holders.
About Exactus:
Exactus Inc. (OTCQB:EXDI) is a leading producer and supplier of
hemp-derived ingredients. Exactus specializes in hemp-derived
ingredients (CBD & CBG) that meet the highest standards of
quality and traceability. The Company strives to stay ahead of
market trends and regulations.
For more information about Exactus: www.exactushemp.com.
Investor Notice:
Investing in our securities involves a high degree of risk. Before
making an investment decision, you should carefully consider the
risks, uncertainties and forward-looking statements described under
"Risk Factors" in Item 1A of our most recent Form 10-K for the
fiscal year ended December 31, 2019 filed with the Securities and
Exchange Commission (the "SEC") on May 22, 2020, and in other
periodic and current reports we file with the SEC. If any of these
risks were to occur, our business, financial condition, or results
of operations would likely suffer. In that event, the value of our
securities could decline, and you could lose part or all of your
investment. The risks and uncertainties we describe are not the
only ones facing us. Additional risks not presently known to us or
that we currently deem immaterial may also impair our business
operations. In addition, our past financial performance may not be
a reliable indicator of future performance, and historical trends
should not be used to anticipate results in the future. See "Safe
Harbor" below.
Safe Harbor - Forward-Looking Statements:
The information provided in this press release may include
forward-looking statements relating to future events or the future
financial performance of Exactus, including statements concerning
harvest expectations, the impact of Exactus’ acquisition of
Green Goddess, LeVor Collection, and interests in the 2019 harvest
on its supply and product line expansion, Exactus’ ability to
monetize its harvest, Exactus’ ability to expand its product
lines and brands, the amount of future orders for Exactus products,
and Exactus’ future revenue, gross margins and working
capital. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "anticipates," "plans," "expects," "intends," "will,"
"potential," "hope" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon current expectations of Exactus and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties. Detailed
information regarding factors that may cause actual results to
differ materially from the results expressed or implied by
statements in this press release relating to Exactus may be found
in Exactus’ periodic and current filings with the SEC,
including the factors described in the sections entitled "Risk
Factors", copies of which may be obtained from the SEC's website at
www.sec.gov. Any forward-looking statement speaks only as of the
date on which such statement is made, and Exactus does not intend
to correct or update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Exactus Contact:
Andrew
Johnson
Chief
Strategy Officer
Exactus
Inc.
509-999-9695
ir@exactusinc.com